Impaired NLRP3 inflammasome signaling diverts pyroptotic to apoptotic caspase activation in macrophages
NLRP3 (NLR family pyrin domain-containing 3) inflammasome is a first line of defense of innate immunity, mediating caspase-1-dependent pyroptosis and cytokine release upon danger signaling. Intervention of NLRP3 innate surveillance may cause defects in this signaling pathway, while the host has evolved alternative ways to combat such intervention. Yet it remains incompletely understood whether NLRP3 sensing of danger signaling can divert pyroptosis to other forms of cell death in circumstances of impaired NLRP3 signaling. In this study, we adopted two macrophage models (delayed delivery of triggering signaling and caspase-1 deficiency) to mimic defects in NLRP3 signaling to address this issue. We found that the NLRP3/ASC platform preferentially recruited caspase-1 rather than caspase-8 in lipopolysaccharide (LPS)-primed macrophages timely triggered with nigericin. However, when the triggering signal (nigericin) was delayed, the recruitment diverted to caspase-8, leading to apoptotic caspase activation. Furthermore, in caspase-1-deficient macrophages, nigericin triggering diverted NLRP3-ASC-caspase-1-driven pyroptosis to caspase-8/-9/-3 activation and GSDME-mediated secondary necrosis. Unexpectedly, VX-765 (a caspase-1 inhibitor) exhibited a pan-caspase inhibitor-like effect, suppressing caspase-8/-9/-3 activation and GSDME cleavage in a dose-dependent manner. Mitochondrial damage was observed in both WT and caspase-1-deficient cells upon nigericin stimulation, suggesting mitochondrial injury being an upstream event in this process. Collectively, our data indicate that NLRP3 inflammasome is poised to divert pyroptotic to apoptotic caspase activation for combating danger signaling when conventional pathway is impaired, highlighting a complex interaction between various forms of cell death pathways.
Authors
- Xiuwen Liang (ORCID: https://orcid.org/0000-0003-3567-2037)
- Fuli Shi
- Yan Cai (ORCID: https://orcid.org/0000-0002-4768-0272)
- Tak-sui Wong
- Xian‐Hui He (ORCID: https://orcid.org/0000-0001-7433-7392)
- Dong‐Yun Ouyang (ORCID: https://orcid.org/0000-0002-4743-942X)
- Rong Xu (ORCID: https://orcid.org/0000-0001-5465-3566)
- Qing-bing Zha
- Nan Sun (ORCID: https://orcid.org/0000-0001-6812-9917)
- Jinhua Li (ORCID: https://orcid.org/0000-0003-1110-7471)
- Yaping Li (ORCID: https://orcid.org/0000-0002-0574-6966)
- Lingzhi Wang (ORCID: https://orcid.org/0000-0002-8276-5394)
- Bo Hu (ORCID: https://orcid.org/0000-0003-3591-1480)
- Ying-qing Gan
Institutions
- Jinan University (CN)
- Chaozhou Central Hospital (CN)
- Spinal Research (GB)
- Third People's Hospital of Hefei (CN)
- The First People's Hospital of Xiaoshan District, Hangzhou (CN)
- First Affiliated Hospital of Jinan University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-24
- DOI
- https://doi.org/10.3389/fimmu.2025.1631152
- Citations
- 1
- Primary Topic
- Inflammasome and immune disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- National Natural Science Foundation of China